The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
Updated recommendations were issued by the IAS-USA regarding the use of ART for treatment and prevention of HIV in adult populations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback